Black Diamond Therapeutics, Inc. Stock OTC Markets
Stocks
BDTX
US09203E1055
Biotechnology & Medical Research
OTC Markets Traded|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - USD | -.--% |
|
-.--% | - |
| Market Cap | 104M 90.07M 83M 77.7M 146M 9.91B 148M 980M 382M 4.82B 391M 383M 16.71B | P/E Ratio 2026 * |
-2.81x | P/E Ratio 2027 * | -1.81x |
|---|---|---|---|---|---|
| Enterprise Value | 104M 90.07M 83M 77.7M 146M 9.91B 148M 980M 382M 4.82B 391M 383M 16.71B | EV / Sales 2026 * |
18.8x | EV / Sales 2027 * | - |
| Free-Float |
99.38% | Yield 2026 * |
-
| Yield 2027 * | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Elizabeth Buck
CTO | Chief Tech/Sci/R&D Officer | 51 | 2021-08-10 |
Mark Velleca
CEO | Chief Executive Officer | 62 | 2023-09-15 |
Erika Jones
DFI | Director of Finance/CFO | 41 | 2024-10-06 |
| Director | Title | Age | Since |
|---|---|---|---|
Garry Menzel
BRD | Director/Board Member | 61 | 2017-02-28 |
Samarth Kulkarni
BRD | Director/Board Member | 47 | 2019-11-30 |
Ali Behbahani
BRD | Director/Board Member | 49 | 2018-11-30 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 104M | |
| +1.03% | +7.52% | +54.74% | +114.98% | 55.58B | |
| +2.72% | +3.06% | +53.28% | +47.85% | 43.47B | |
| +12.08% | +2.57% | -13.90% | -17.72% | 22.64B | |
| +1.75% | +4.31% | +1.45% | +404.00% | 20.96B | |
| +3.81% | -4.13% | +16.62% | -30.70% | 15.79B | |
| +0.15% | +0.50% | +9.10% | -40.04% | 15.3B | |
| +2.94% | +0.78% | +27.12% | +178.21% | 13.45B | |
| +5.27% | +6.41% | +21.05% | - | 11.74B | |
| +1.61% | +1.17% | +90.79% | +212.97% | 10.96B | |
| Average | +1.64% | +0.26% | +28.92% | +108.69% | 23.32B | |
| Weighted average by Cap. | +1.72% | +1.60% | +33.75% | +101.80% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 5.56M 4.8M 4.42M 4.14M 7.76M 528M 7.88M 52.21M 20.36M 257M 20.85M 20.41M 890M | - |
| Net income | -40.47M -34.96M -32.21M -30.15M -56.51M -3.85B -57.38M -380M -148M -1.87B -152M -149M -6.48B | -70.04M -60.5M -55.75M -52.18M -97.8M -6.66B -99.31M -658M -257M -3.24B -263M -257M -11.22B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BDTX Stock
- BDTX Stock
Select your edition
All financial news and data tailored to specific country editions
